Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Post by somweyungguyon Oct 16, 2016 10:22am
118 Views
Post# 25348431

Financing partner Cormark and their 4 CENT target

Financing partner Cormark and their 4 CENT targetI wonder what is up with this company?
Why not drop coverage?
4 CENTS would seem only DAMAGING


How closely does Spectral work with such partners?

Include Mackie ( 5 CENT target ) in this discussion as well.

Cormark kept Spectral under review for 360 Days ( June 4 2015 to May 30 2016 )

When the report arrived it included details of a 3% inside ownership.
Regardless of "Insider Definition" this is a MOST misleading stat.
Toray and Birch Hill Private Equity own 40% combined
The company traded 1.2M shares for ALL of 2008
This company is held more tightly than Kermit's tooshie


Depsite waiting 360 days, the analyst failed to wait just a few more hours, as on May 31st the company held it's AGM and disclosed important details.

Neither Cormark or Mackie ever told the market about the FDA COMPASSIONATE CARE Approval

All I needed to read in the Cormark report was the detail on the toxicity of a 1970's study on polymyxin B, the anti-biotic used in the Toraymyxin ( PMX ) filter.  Toraymyxin was approved for used in Japan in 1994, and has been safely used on over 180K people now.  What relevance does a 1970s study in directly administered polymyxin B have?

What is really going on here?

Sqr
Bullboard Posts